Search results for "hereditary angioedema"

showing 10 items of 113 documents

Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, a…

2008

Background We published the Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema (HAE; C1 inhibitor [C1-INH] deficiency) in 2004. Objective To ensure that this consensus remains current. Methods In collaboration with the Canadian Network of Rare Blood Disorder Organizations, we held the second Canadian Consensus discussion with our international colleagues in Toronto, Ontario, on February 3, 2006, and reviewed its content at the Fifth C1 Inhibitor Deficiency Workshop in Budapest on June 2, 2007. Papers were presented by international investigators, and this consensus algorithm approach resulted. Results This consensus algorithm …

Pulmonary and Respiratory MedicineConsensus algorithmmedicine.medical_specialtyCanadaC1 inhibitor deficiencyConsensus Development Conferences as TopicInternational CooperationImmunologyMEDLINEEcallantidemedicineImmunology and AllergyHumansHungarybusiness.industryAngioedemas HereditaryState of the art reviewEvidence-based medicinemedicine.diseaseBlood DisorderFamily medicineHereditary angioedemaControlled Clinical Trials as TopicbusinessAlgorithmsmedicine.drugAnnals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology
researchProduct

European Consensus for Gynecologycal and Obstetric Management of Women with Hereditary Angioedema due to C1-Inhibitor Deficiency (HAE): PREHAEAT

2007

Settore MED/16 - Reumatologiamedicine.medical_specialtyPediatricsC1 inhibitor deficiencybusiness.industryImmunologyHereditary angioedemamedicineImmunology and Allergymedicine.diseasebusinessSurgeryJournal of Allergy and Clinical Immunology
researchProduct

C1-Esterase Inhibitor Concentrate for Acute Laryngeal Hereditary Angioedema (HAE) Attacks: Different Treatment Response Based on Dosing Regimen?

2016

Treatment responsemedicine.medical_specialtybusiness.industryImmunologyDosing regimenmedicine.diseaseGastroenterologyC1 esteraseAnesthesiaInternal medicineHereditary angioedemaImmunology and AllergyMedicinebusinessJournal of Allergy and Clinical Immunology
researchProduct

Missense mutations of coagulation factor XII in hereditary angioedema with normal complement C1 inhibitor

2007

biologybusiness.industryImmunologyCoagulation Factor XIImedicine.diseaseComplement (complexity)C1-inhibitorHereditary angioedemaImmunologymedicinebiology.proteinMissense mutationbusinessMolecular BiologyMolecular Immunology
researchProduct

C1-Esterase Inhibitor Concentrate For Acute Attacks Of Laryngeal Edema In Hereditary Angioedema (HAE): Fixed Dosing Vs Body Weight-Adjusted Dosing

2014

business.industryAnesthesiaImmunologyHereditary angioedemaImmunology and AllergyMedicineDosingbusinessBody weightLaryngeal Edemamedicine.diseaseC1 esteraseJournal of Allergy and Clinical Immunology
researchProduct

Treatment of Hereditary Angioedema with the Mutation c.988A>G (p.K330E) in the Plasminogen Gene

2020

business.industryImmunologyMutation (genetic algorithm)Plasminogen GeneHereditary angioedemamedicineImmunology and Allergymedicine.diseasebusinessMolecular biologyJournal of Allergy and Clinical Immunology
researchProduct

Hereditary Angioedema with Normal C1-INH with Versus without a Specific Mutation in the F12 Gene

2015

business.industrySpecific mutationImmunologyHereditary angioedemaImmunologymedicineImmunology and Allergymedicine.diseasebusinessGeneJournal of Allergy and Clinical Immunology
researchProduct

Icatibant, a Selective Bradykinin B2 Receptor Antagonist Used in Hereditary Angioedema Due to C1 Inhibitor Deficiency

2010

chemistry.chemical_compoundC1 inhibitor deficiencychemistryIcatibantbusiness.industryImmunologyHereditary angioedemamedicineImmunology and AllergyBradykinin b2 receptor antagonistPharmacologymedicine.diseasebusinessJournal of Allergy and Clinical Immunology
researchProduct

The care pathway for children with urticaria, angioedema, mastocytosis

2015

Cutaneous involvement characterized by urticarial lesions with or without angioedema and itch is commonly observed in routine medical practice. The clinical approach may still remain complex in real life, because several diseases may display similar cutaneous manifestations. Urticaria is a common disease, characterized by the sudden appearance of wheals, with/without angioedema. The term Chronic Urticaria (CU) encompasses a group of conditions with different underlying causes and different mechanisms, but sharing the clinical picture of recurring wheals and/or angioedema for at least 6 weeks. Hereditary Angioedema (HAE) is a rare disorder characterized by recurrent episodes of non-pruritic,…

lcsh:Immunologic diseases. AllergyPulmonary and Respiratory MedicineAllergyUrticariaEpidemiologyImmunologyReviewClinical practiceAngioedema; Children; Clinical practice; Diagnosis; Epidemiology; Itch; Management; Mastocytosis; Skin; UrticariaItchC1-inhibitor030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineimmune system diseasesEdemaDiagnosismedicineImmunology and AllergyAngioedemaskin and connective tissue diseasesChildrenSkinbiologyAngioedemabusiness.industryAutosomal dominant traitAngioneurotic oedemamedicine.diseasePathophysiologyManagement3. Good healthUrticaria Angioedema Mastocytosis Skin Itch Children Epidemiology Diagnosis Management Clinical practice.030228 respiratory systemImmunologyHereditary angioedemabiology.proteinmedicine.symptomlcsh:RC581-607businessMastocytosisWorld Allergy Organization Journal
researchProduct

Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled rando…

2019

Abstract Background Hereditary angioedema (HAE) is a debilitating disorder resulting from C1-esterase inhibitor (C1-INH) deficiency. In the COMPACT phase 3 study the prophylactic use of a subcutaneous C1 inhibitor (C1-INH [SC], HAEGARDA®, CSL Behring) twice weekly significantly reduced the frequency of acute edema attacks. Analysis of treatment effects by subgroups, onset of effect, and other exploratory analysis have not been reported. Methods This is a post hoc exploratory analysis on data from the randomized, placebo-controlled COMPACT study. 90 patients with C1-INH-HAE were randomized to 1 of 4 treatment sequences: C1-INH (SC) 40 or 60 IU/kg of body weight twice weekly for 16 weeks, pre…

lcsh:Immunologic diseases. Allergymedicine.medical_specialtyPhases of clinical researchSubgroup analysisReplacement therapyPlacebolaw.invention03 medical and health sciences0302 clinical medicineC1-INH (SC)Randomized controlled trialHAEGARDA®lawInternal medicinePost-hoc analysisMedicine030212 general & internal medicineDosingCOMPACT studyHereditary angioedemabusiness.industryResearchSubcutaneousGeneral Medicinemedicine.diseaseClinical trialLong-term prophylaxis030228 respiratory systemC1-esterase inhibitor proteinHereditary angioedemabusinesslcsh:RC581-607Allergy, Asthma & Clinical Immunology
researchProduct